These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 1703909

  • 1. [Recombinant human erythropoietin (rh-EPO) in chronic, dialysis-dependent renal failure: effects on macro- and microcirculation and hematologic parameters].
    Köhler M, Mörsdorf S, Jung F, Braun B, Waldhausen P, Pindur G, Weber U, Bosslet R, Bambauer R, Jutzler GA.
    Beitr Infusionsther; 1990; 26():89-95. PubMed ID: 1703909
    [Abstract] [Full Text] [Related]

  • 2. [Effect of recombinant human erythropoietin (rHu-EPO) on anemia and selected biochemical parameters in patients in the pre-dialysis period].
    Sułowicz W, Drozdz M, Hanicki Z, Kraśniak A, Kuźniewski M.
    Przegl Lek; 1992; 49(1-2):50-3. PubMed ID: 1455007
    [Abstract] [Full Text] [Related]

  • 3. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
    Jalil R, Vaccarezza A, Jara A, Lira P, Vial S, Serrano V.
    Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783
    [Abstract] [Full Text] [Related]

  • 4. [Effect of erythropoietin therapy on alpha receptor density in chronic dialysis patients].
    Fritschka E, Neumayer HH, Seddighi S, Distler A, Philipp T.
    Med Klin (Munich); 1991 Jul 15; 86(7):353-9. PubMed ID: 1656181
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of indicators of erythropoiesis stimulated by recombinant human erythropoietin in renal anemia.
    Schmidt G, Stamminger G, Daniel A, Gross J, Syllm-Rapoport I, Lun A, Zoellner K.
    Biomed Biochim Acta; 1990 Jul 15; 49(2-3):S275-9. PubMed ID: 2386517
    [Abstract] [Full Text] [Related]

  • 6. [Effect of recombinant human erythropoietin--rHu-EPO on the metabolism of children treated by long-term hemodialysis].
    Pietrzyk JA, Smolnik T, Szymowska M, Dyras P, Lenik J.
    Przegl Lek; 1992 Jul 15; 49(1-2):55-60. PubMed ID: 1455008
    [Abstract] [Full Text] [Related]

  • 7. [Erythropoietin--the first hematologic hormone in clinical use].
    Rhyner K.
    Schweiz Med Wochenschr; 1988 Mar 19; 118(11):375-80. PubMed ID: 3287601
    [Abstract] [Full Text] [Related]

  • 8. Does additional treatment with fish oil mitigate the side effects of recombinant human erythropoietin in dialysis patients?
    de Fijter CW, Popp-Snijders C, Oe LP, Tran DD, van der Meulen J, Donker AJ.
    Haematologica; 1995 Mar 19; 80(4):332-4. PubMed ID: 7590502
    [Abstract] [Full Text] [Related]

  • 9. [Effect of using recombinant human erythropoietin on the effectiveness of hemodialysis in children with terminal renal failure].
    Pietrzyk JA, Dyras P, Smolnik T, Szymowska M.
    Przegl Lek; 1992 Mar 19; 49(1-2):61-5. PubMed ID: 1280842
    [Abstract] [Full Text] [Related]

  • 10. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
    Mohini R.
    Semin Nephrol; 1989 Mar 19; 9(1 Suppl 1):16-21. PubMed ID: 2648516
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Blood rheology and 2,3-diphosphoglycerate levels after erythropoietin treatment.
    Crowley JP, Chazan JA, Metzger JB, Pono L, Valeri CR.
    Ann Clin Lab Sci; 1993 Mar 19; 23(1):24-32. PubMed ID: 8430997
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
    Carozzi S, Nasini MG, Santoni O, Tirotta A, Sanna A.
    ASAIO J; 1997 Mar 19; 43(5):M535-8. PubMed ID: 9360100
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The rate of increase in hematocrit, humoral vasoactive substances and blood pressure changes in hemodialysis patients treated with recombinant human erythropoietin or blood transfusion.
    Ono K, Hisasue Y.
    Clin Nephrol; 1992 Jan 19; 37(1):23-7. PubMed ID: 1531789
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patients.
    Pawlak K, Pawlak D, Mysliwiec M.
    Am J Nephrol; 2007 Jan 19; 27(3):221-5. PubMed ID: 17384500
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.